Autosomal dominant polycystic kidney disease (ADPKD) is caused by heterozygous mutations in either PKD1 or PKD2, genes that encode polycystin-1 and polycystin-2, respectively 1 . We show here that tumor necrosis factor-a (TNF-a), an inflammatory cytokine present in the cystic fluid of humans with ADPKD, disrupts the localization of polycystin-2 to the plasma membrane and primary cilia through a scaffold protein, FIP2, which is induced by TNF-a. Treatment of mouse embryonic kidney organ cultures with TNF-a resulted in formation of cysts, and this effect was exacerbated in the Pkd2 +/À kidneys. TNF-a also stimulated cyst formation in vivo in Pkd2 +/À mice. In contrast, treatment of Pkd2 +/À mice with the TNF-a inhibitor etanercept prevented cyst formation. These data reveal a pathway connecting TNF-a signaling, polycystins and cystogenesis, the activation of which may reduce functional polycystin-2 below a critical threshold, precipitating the ADPKD cellular phenotype.
Autosomal dominant polycystic kidney disease (ADPKD) is caused by heterozygous mutations in either PKD1 or PKD2, genes that encode polycystin-1 and polycystin-2, respectively 1 . We show here that tumor necrosis factor-a (TNF-a), an inflammatory cytokine present in the cystic fluid of humans with ADPKD, disrupts the localization of polycystin-2 to the plasma membrane and primary cilia through a scaffold protein, FIP2, which is induced by TNF-a. Treatment of mouse embryonic kidney organ cultures with TNF-a resulted in formation of cysts, and this effect was exacerbated in the Pkd2 +/À kidneys. TNF-a also stimulated cyst formation in vivo in Pkd2 +/À mice. In contrast, treatment of Pkd2 +/À mice with the TNF-a inhibitor etanercept prevented cyst formation. These data reveal a pathway connecting TNF-a signaling, polycystins and cystogenesis, the activation of which may reduce functional polycystin-2 below a critical threshold, precipitating the ADPKD cellular phenotype.
It was proposed that after germline inactivation of a single allele of either PKD1 or PKD2, cystogenesis in ADPKD results from the clonal expansion of tubule epithelial cells acquiring 'second hit' mutations that inactivate the second, functional copy of these PKD genes 2 . However, in mice with a hypomorphic Pkd1 allele, reduction in Pkd1 expression was sufficient to initiate cystogenesis 3 . The high frequency at which cysts develop in human ADPKD suggests that nongenetic factors may also contribute to cyst formation 4 . One of the possible physiological factors is the proinflammatory cytokine, TNF-a (ref. 5 ). TNF-a mRNA and protein are markedly increased after hypertensive stress 6 and renal injury 7 , conditions that are associated with ADPKD 4 . Urinary tract infections are also frequent complications in ADPKD 8 . TNF-a was found to increase progressively with age in cystic kidneys of congenital polycystic kidney (cpk) mice 9 , a rodent model of autosomal recessive polycystic kidney disease (ARPKD), and was also present in human ADPKD cyst fluids 10 .
To investigate the connection between TNF-a and ADPKD, we have focused on FIP2, a TNF-a-induced protein 11 . Immunoblot analysis confirmed that treatment with TNF-a elevated the expression of FIP2, but not polycystin-2, by three-to fourfold (Fig. 1a) , and polycystin-2 and FIP2 coimmunoprecipitated from inner medullary collecting duct (IMCD) cell lysates when antibody against either protein was used (Fig. 1b) .
Because FIP2 is involved in vesicular trafficking 12, 13 , we tested the possibility that TNF-a could affect the normal localization of polycystin-2, a calcium channel 1 , through induction of FIP2 (Fig. 1) .
Immunofluorescence staining with an antibody to polycystin-2 (96525, ref. 14) revealed that although endogenous polycystin-2 localized to the plasma membrane and in 495% of the primary cilia observed in untreated IMCD cells (Fig. 1c and Supplementary Movie 1 online), cells treated with TNF-a showed a striking loss of polycystin-2 staining from these locations (100% observed). Instead, polycystin-2 was enriched within perinuclear regions ( Fig. 1d and Supplementary Movie 2 online), overlapping partially with a Golgi marker ( Supplementary Fig. 1a online) . This effect of TNF-a was further confirmed with antibody YCC2 (ref. 15 ; Supplementary  Fig. 1b,c) , although this antibody only recognized polycystin-2 on the cilia and not on other membrane structures 16 . The loss of membrane localization of polycystin-2 was not due to cell death, as the TNF-a-treated cells showed normal morphology and were negative for TUNEL staining ( Supplementary Fig. 2 online) . To test whether the effect of TNF-a on polycystin-2 localization was FIP2 dependent, we used small interfering RNA (siRNA) to knock down FIP2 expression ( Supplementary Fig. 3a ,b online), which restored normal polycystin-2 localization in TNF-a-treated cells (Fig. 1g,h and Supplementary Fig. 3c,d ).
Polycystin-2 functions in a complex with polycystin-1 (refs. 17,18) , and thus we performed immunoprecipitation assays to test the effect of TNF-a on polycystin-1-polycystin-2 complex formation. TNF-a treatment disrupted the polycystin-1-polycystin-2 interaction, even though the expression levels of polycystin-1 and polycystin-2 remained the same as those in untreated cells ( Supplementary Fig. 4a,b online) . Ciliary localization of polycystin-1, however, was not affected in TNF-a-treated IMCD cells ( Supplementary Fig. 4cÀf) .
The above cellular data raised the possibility that TNF-a promotes cyst formation by disrupting the normal localization and a key interaction of polycystin-2. To test this hypothesis, we modified a mouse embryonic kidney organ culture assay 19 by using embryonic day 15.5 (E15.5) kidneys and a low concentration of cyclic AMP (cAMP), such that there was no cyst formation (0/32 kidneys observed) in the absence of TNF-a (see Methods). Treatment for 5 d with TNF-a resulted in numerous cyst-like structures in wild-type embryonic kidneys ( Fig. 2a ; 20/20 cultured kidneys treated with 6.25À12.5 ng/ml TNF-a). Notably, in Pkd2 +/À embryonic kidneys, cyst formation occurred at a TNF-a concentration as low as 1.5 ng/ml. (Fig. 2b) . The cysts that formed in TNF-a-treated kidneys were positive for staining with fluorescently labeled Dolichos biflorus agglutinin (DBA) or Lotus tetragonobulusagglutinin (LTA), thus identifying collecting ducts or proximal tubules, respectively ( Supplementary  Fig. 5 online) . These results suggested that the TNF-a-induced cysts originated from these nephron segments.
Immunoblot analysis confirmed that TNF-a increased the expression of FIP2 by four-to fivefold in wild-type embryonic kidneys (Fig. 2c) . Of note, FIP2 abundance in untreated Pkd2 +/À kidneys was markedly higher (more than twofold) than in wild-type kidneys, suggesting that polycystin-2 negatively affects the expression of FIP2. FIP2 abundance in Pkd2 +/À kidneys was further stimulated two-to threefold by TNF-a treatment (Fig. 2c) . Moreover, a similar pattern of expression for TNF-a receptor, TNFR-I, was also detected across the kidney samples examined (Fig. 2c) , suggesting that exposure to TNFa or Pkd2 heterozygosity may render the kidney more sensitive to TNF-a through an increase in TNFR-I abundance. TNF-a converting enzyme (TACE), although undetectable in wild-type kidneys, was clearly detectable in Pkd2 +/À embryonic kidneys, and its abundance was further elevated approximately threefold after TNF-a treatment (Fig. 2c) .
The effective concentrations of TNF-a necessary for the cyst induction observed in kidney organ cultures were in the ng/ml range, much higher than the previously reported concentration of TNF-a in human cyst fluids (in the range of 10À73 pg/ml) 10 . To investigate this discrepancy, we quantified the concentration of TNF-a in human ADPKD cyst fluids collected from ten isolated ADPKD kidneys on ice and immediately frozen in liquid nitrogen. Our results show a considerable accumulation of TNF-a, with concentrations in the ng/ml range in small cysts (Fig. 2d ) and an inverse relationship between cyst volume and TNF-a concentration. However, the total amount of TNF-a was higher in larger cysts (Fig. 2e) , indicating that TNF-a accumulated as cysts grew. The highest level of TNF-a (3.8 ng/ ml) was observed in the most freshly collected cyst fluid that had not been frozen (Fig. 2d) . The difference between our measurements and those described previously may be due to differences in the size of the cysts or the method of fluid collection and storage. Notably, TACE was also found in cyst fluids at a concentration of 9.0 ± 0.9 ng/ml (n ¼ 15), in contrast to being undetectable in normal human urine samples. Soluble TNFR-I and TNFR-II were also present in cyst fluids at 2.2 ± 0.3 ng/ml and 2.1 ± 0.4 ng/ml (n ¼ 15), respectively, which is slightly elevated compared to their abundance in normal urine (B1.5 ng/ml). Previous work has shown that this moderate level of soluble TNFRs augments rather than inhibits TNF-a activity through a stabilization or buffering effect 20, 21 . The presence of both TACE and soluble TNFRs in ADPKD cyst fluids could contribute to the accumulation of TNF-a, which may be directly produced by renal cells 7 . Immune cells, which infiltrate the kidney in response to renal lesions and infections, are another possible source for TNF-a (ref. 7) .
To test further whether FIP2 abundance was elevated in human cystic kidneys, we compared the amount of FIP2 protein between primary cultures of normal human kidney cells (NHK cells) and cyst-lining cells from humans with ADPKD (PKD cells). The amount of FIP2 in the PKD cells was approximately twofold higher compared to that in NHK cells (Fig. 2f) , similar to the observed FIP2 level difference between Pkd2 +/À and Pkd2 +/+ mouse embryonic kidneys (Fig. 2c) . The amount of TNFR-I was also increased (approximately fourfold) in cyst-lining cells over NHK cells (Fig. 2c) .
To test the effect of TNF-a on cyst formation in vivo, we intraperitoneally injected 4-week-old Pkd2 +/À mice with TNF-a (0.5 mg per gram mouse body weight, one injection per week for 4 weeks). No cysts were observed in the control group (n ¼ 10); by contrast, four of the ten TNF-a-treated mice developed unilateral cysts ( Table 1) . This experiment was also repeated in 8.5-week-old mice (0.5 mg per gram mouse body weight, one injection per week for 10 weeks). Whereas the control group developed cysts at the expected frequency (21.3%) 22 , 42.8% (6 out of 14 mice) of the experimental group developed cysts ( online). This result shows that TNF-a stimulates cyst development in Pkd2 +/À mice. To test whether inhibition of TNF-a could alleviate cyst formation, we treated 8.5-week-old Pkd2 +/À mice with etanercept, a TNF-a inhibitor (subcutaneously administered at 125 mg per mouse per week). Etanercept is a US Food and Drug Administration-approved drug that neutralizes circulating TNF-a with well-characterized pharmacodynamics 23 . After 10 weeks of treatment, the control group developed cysts at the expected frequency, but none of etanercepttreated mice developed kidney cysts (n ¼ 50; Fig. 3a,b ). Fisher's exact test yielded a P value of 0.0005, indicating that neutralization of TNF-a significantly prevented cyst formation in Pkd2 +/À mice. Elevated levels of TNF-a in the polycystic kidneys of individuals with ADPKD would be expected to exacerbate their disease by driving the growth and enlargement of their kidney cysts. As such, future studies are needed to determine whether therapeutic use of etanercept could help slow down the enlargement of these cysts and block the formation of new cysts.
Taken together, these findings suggest that TNF-a is a potent factor that promotes renal cyst development, especially in the genetic background associated with ADPKD, and are consistent with the previous finding that a TACE inhibitor reduced cyst formation in the Balb/C polycystic kidney (bpk) mouse model of ARPKD 24 . The functional network that connects TNF-a, polycystin and cyst development contains three double-negative feedback loops (Fig. 3c) , which are key motifs in biological networks that could generate stable responses to small, transient signals 25 . We hypothesize that this network structure could contribute substantially to the transition from normal tubule development to cystic disease onset in response to perturbation of polycystin-2 by TNF-a in the heterozygous genetic background associated with ADPKD. A recent study found that TNFa can also activate the mammalian target of rapamycin (mTOR) pathway through inhibitor of kB kinase-b (ref. 26) , and inhibition of mTOR has been shown to revert renal cystogenesis in Pkd mouse models 27 . Thus, the effect of etanercept observed in this work may not be limited to the mechanism suggested in this study. Moreover, such mechanisms do not argue against key contributions from genetic changes, such as loss of heterozygosity 2 . Nonetheless, unraveling nongenetic factors that contribute to the onset of cystogenesis may be a useful approach toward therapeutic intervention of ADPKD.
METHODS
Cell culture. We cultured IMCD (American Type Culture Collection CRL-2123) cells in DMEM/F12 medium supplemented with 10% (vol/vol) FBS (Invitrogen). For TNF-a treatment experiments, it was important that cells were cultured for 7-9 d at 37 1C to allow sufficient time for cilia growth before addition of TNF-a. The concentration of TNF-a (Genzyme Diagnostic) was 200 ng/ml for all cell culture experiments. For the FIP2 knock-down experiment, we cultured cells for 7 d before siRNA transfection. After 48 h, we either harvested cells for western blot analysis or treated them with TNF-a for 16 h, followed by fixation for immunostaining.
Mouse and human samples. All experiments involving higher vertebrates were approved by the Institutional Animal Care and Use Committee of the Stowers Institute for Medical Research. We obtained mutant embryos by timed mating; the morning of the vaginal plug was considered to be E0.5. We obtained human ADPKD kidneys from the surgery department at Kansas University Medical Center or hospitals participating in the Polycystic Kidney Research Retrieval Program. The protocol for the use of discarded human tissues complies with federal regulations and was approved by the Institutional Review Board at Kansas University Medical Center. The human subjects gave informed consent to the hospitals that retrieved the tissue. We receive the de-identified samples from the hospitals using a 'limited data set' agreement.
Embryonic kidney organ culture. We dissected embryonic kidneys from embryos of C57BL/6 Pkd2 +/À mice or their wild-type counterparts at E15.5 in PBS (with calcium and magnesium) plus penicillin-streptomycin-glutamine (Gibco). We cultured the dissected kidneys at 37 1C in DMEM/F12 containing 2 mM L-glutamine, 10 mM HEPES (Gibco), 5 mg/ml insulin, 5 mg/ml transferrin, 2.8 mM selenium, 25 ng/ml prostaglandin E1, 32 pg/ml 2,3,5-triido-L-thyronine (T3) and 250 U/ml penicillin-streptomycin. We cultured the kidneys with or without TNF-a (Genzyme Diagnostic) at different concentrations for 48 h and then added 50 mM 8-bromo-cAMP (Sigma) to the culture medium and then continued culture for 5 d. We then fixed the cultured kidneys with 4% paraformaldehyde in PBS for 6 h, washed them with PBS twice for 5 min each and then transferred them to 70% ethanol for short-term storage at room temperature or for more extended storage at 4 1C. We subsequently processed the fixed kidney samples for H&E staining and lectin staining following common histology protocol.
Terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Cells treated with or without TNF-a were fixed with 4% paraformaldehyde. We performed TUNEL assays with a fluorescent apoptosis-detection system (R&D Systems). We used fixed cells treated with TACS-nuclease (Trevigen) as the positive control. between PC2 function and the physiological response that leads to TNF-a production, between PC2 abundance and FIP2 expression and between PC2 and TNFR expression. +, positive effect; À, negative effect. In red, genetic and nongenetic factors that could influence the pathway leading to cystogenesis.
Immunoprecipitation and western blot analysis. We performed immunoprecipitation and western blotting on whole-cell lysates as previously described 28 RNA interference to inhibit FIP2 expression. The oligonucleotide sequences used for FIP2 RNA interference (Dharmacon) are as follows: siRNA-05 sense sequence, 5¢-GCUAUGAAAGGGCGAUUUGUU-3¢; siRNA-05 antisense sequence, 5¢-PCAAAUCGCCCUUUCAUAGCUU-3¢; siRNA-06 sense sequence, 5¢-UGAGCUGCCUGACUGAGAAUU-3¢; siRNA-06 antisense sequence, 5¢-PUU CUCAGUCAGGCAGCUCAUU-3¢; siRNA-07 sense sequence, 5¢-GAAAUGCAG UGCCGACACGUU-3¢; siRNA-07 antisense sequence, 5¢-PCGUGUCGGCACU GCAUUUCUU-3¢; siRNA-08 sense sequence, 5¢-CCAUGAAGCUAAAUAAU CAUU-3¢; siRNA-08 antisense sequence, 5¢-PUGAUUAUUUAGCUUCAUG GUU-3¢. Both sense and antisense oligonucleotides were used to form short RNA duplexes. We transfected them with the DharmaFECT siRNA transfection reagent (Dharmacon).
Immunofluorescence microscopy. We carried out immunofluorescence as previously described 28 . We used primary antibodies at the following dilutions: antibody to FIP2 (1:100), antibody to polycystin-1 (1:500), antibody to polycystin-2 (1:500) and antibody to FLAG (1:500). The secondary antibodies used included FITC-conjugated goat antibody to rabbit IgG (Molecular Probes) and Texas Red-conjugated goat antibody to mouse IgG (1:500 dilution; Molecular Probes). We captured images on an inverted microscope (Axiovert 200M, Carl Zeiss) equipped with a spinning-disc confocal head (Yogogawa), Argon-Krypton laser system (Prairie Technologies), and ORCA-ER chargedcoupled device camera (Hamamatsu). We acquired images with Metamorph software (Molecular Devices) and performed three-dimensional image reconstruction with Volocity (Improvision) software.
Collection of human autosomal dominant polycystic kidney disease cyst fluids. We collected cyst fluids from ten ADPKD kidneys (nine end-stage kidneys and one early-stage kidney removed owing to severe pain) by aspiration with a syringe and a needle. We maintained the kidneys at 4 1C throughout the cyst fluid collection. We cleared the collected cyst fluids by centrifugation and then snap-froze them in liquid nitrogen and stored them at À80 1C until we analyzed them. We described cysts as small, medium and large on the basis of cyst fluid volumes at 1À2.5 ml, 2.5À20 ml and 420 ml, respectively.
Enzyme-linked immunosorbent assay. We measured the concentrations and total amounts of TNF-a in individual cyst fluids with the DuoSet ELISA Development kit for human TNF-a/TNFSF1A (R&D Systems). We measured the concentrations of TACE and soluble TNFRs in ADPKD cyst fluids and normal human urine samples with the DuoSet ELISA Development kits for human TACE/ADAM17 (R&D Systems), human sTNF-RI/TNFRSF1A (R&D Systems) and human sTNF RII/TNFRSF1B (R&D Systems), respectively, following the manufacturer's instructions.
Tumor necrosis factor-a and etanercept treatments of mice. Pkd2-mutant mice (Pkd2-183) were kindly provided by S. Somlo (Yale University). For TNFa (Genzyme Diagnostic) treatments, we injected mice intraperitoneally weekly, from week 4 (day 28) to week 8.5 (day 60) or from week 8. Additional methods. Detailed methodology is described in Supplementary Methods.
Statistical analyses. A Fisher's exact test was used for statistical analysis 29 , and statistical significance implies P o 0.05.
